NO20061169L - Prober for sykdommer hvor amyloid akkumulerer midler for a farge amyloidlegemidler for behandling og profylakse av sykdommer med akkumulert innhold og prober for diagnoser av nevrofibrilaere knuter og legemidler for a farge nevrofibrilaere knuter - Google Patents

Prober for sykdommer hvor amyloid akkumulerer midler for a farge amyloidlegemidler for behandling og profylakse av sykdommer med akkumulert innhold og prober for diagnoser av nevrofibrilaere knuter og legemidler for a farge nevrofibrilaere knuter

Info

Publication number
NO20061169L
NO20061169L NO20061169A NO20061169A NO20061169L NO 20061169 L NO20061169 L NO 20061169L NO 20061169 A NO20061169 A NO 20061169A NO 20061169 A NO20061169 A NO 20061169A NO 20061169 L NO20061169 L NO 20061169L
Authority
NO
Norway
Prior art keywords
amyloid
diseases
probes
neurofibrilar
nodules
Prior art date
Application number
NO20061169A
Other languages
English (en)
Inventor
Yukitsuka Kudo
Masako Suzuki
Takahiro Suemoto
Nobuyuki Okamura
Tsuyoshi Shiomitsu
Hirosho Shimazu
Original Assignee
Bf Res Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2004/011546 external-priority patent/WO2005016888A1/ja
Application filed by Bf Res Inst Inc filed Critical Bf Res Inst Inc
Publication of NO20061169L publication Critical patent/NO20061169L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Den foreliggende oppfinnelse tilveiebringer forbindelser med høy affinitet for amyloid P-protein for diagnose av sykdommer hvori amyloid P-protein akkumulerer, for midler for spesifikk farging av amyloid P-protein, og for behandling og/eller profylakse av sykdommer hvori amyloid P-protein akkumulerer. Den foreliggende oppfinnelse tilveiebringer også prober og fargemidler for neurofibrillære knuter.
NO20061169A 2003-08-13 2006-03-13 Prober for sykdommer hvor amyloid akkumulerer midler for a farge amyloidlegemidler for behandling og profylakse av sykdommer med akkumulert innhold og prober for diagnoser av nevrofibrilaere knuter og legemidler for a farge nevrofibrilaere knuter NO20061169L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003293056 2003-08-13
PCT/JP2003/015229 WO2005016384A1 (ja) 2003-08-13 2003-11-28 アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
PCT/JP2004/011546 WO2005016888A1 (ja) 2003-08-13 2004-08-11 アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤

Publications (1)

Publication Number Publication Date
NO20061169L true NO20061169L (no) 2006-05-11

Family

ID=34190974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061169A NO20061169L (no) 2003-08-13 2006-03-13 Prober for sykdommer hvor amyloid akkumulerer midler for a farge amyloidlegemidler for behandling og profylakse av sykdommer med akkumulert innhold og prober for diagnoser av nevrofibrilaere knuter og legemidler for a farge nevrofibrilaere knuter

Country Status (12)

Country Link
US (1) US20060018825A1 (no)
JP (1) JPWO2005016888A1 (no)
KR (1) KR20060037441A (no)
CN (1) CN1867552A (no)
AU (1) AU2003304416A1 (no)
BR (1) BRPI0413556A (no)
CR (1) CR8230A (no)
EC (1) ECSP066363A (no)
IL (1) IL173549A0 (no)
NO (1) NO20061169L (no)
RU (1) RU2006107563A (no)
WO (1) WO2005016384A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090185975A1 (en) * 2005-12-26 2009-07-23 Tohoku University Diagnostic probe for conformation disease
EP2103611A4 (en) 2006-12-25 2010-06-30 Univ Tohoku benzoxazole
US20100272642A1 (en) * 2007-07-04 2010-10-28 Tohoku University Pet probe having an alkoxy group substituted by fluorine and hydroxy group
CN104974024B (zh) 2008-03-21 2017-11-14 综合医院公司 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
CL2008002267A1 (es) * 2008-07-31 2009-07-03 Servicios Cientificos Neuroinnovation Ltda Uso de compuestos derivados de pirinmetilsulfinilbencimadazol y piperidinilaminobencimidazol como marcadores especificos para enfermedades neurodegenerativas y patologias tau; y como metodo de diagnostico de enfermedad de alzheimer, y formulacion farmaceutica que comprende dichos compuestos marcados radiactivamente o con fluorescencia.
JP5591720B2 (ja) * 2009-01-29 2014-09-17 株式会社林原 抗神経変性疾患剤
JPWO2010087313A1 (ja) * 2009-01-29 2012-08-02 株式会社林原生物化学研究所 神経突起伸展促進剤
WO2010087315A1 (ja) * 2009-01-29 2010-08-05 株式会社林原生物化学研究所 抗アルツハイマー病剤
JP2010189359A (ja) * 2009-02-20 2010-09-02 Kyoto Univ ベンゾチアゾール誘導体含有診断用組成物
CA2756137C (en) * 2009-03-23 2015-11-24 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
IN2013MN00501A (no) 2010-10-08 2015-05-29 N30 Pharmaceuticals Inc
EP2651871A4 (en) 2010-12-16 2015-07-22 Nivalis Therapeutics Inc NEW SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHION REDUCTASE INHIBITORS
CN102557969B (zh) * 2011-11-01 2015-03-18 中国科学技术大学 环酮类衍生物及其作为淀粉样蛋白沉积物和神经纤维缠结的显像剂和聚集抑制剂的用途
JP5422782B1 (ja) * 2012-12-21 2014-02-19 独立行政法人放射線医学総合研究所 脳内に蓄積したタウタンパク質をイメージングするための新規化合物
US10907197B2 (en) * 2014-08-29 2021-02-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
PT3186233T (pt) 2014-08-29 2021-12-02 Chdi Foundation Inc Sondas para imagem de proteína de huntingtina
FR3027770B1 (fr) * 2014-10-30 2018-10-19 Universite De Haute-Alsace Utilisation du sous-salicylate de bismuth ou de l'un de ses derives en tant qu'agent phytopharmaceutique
WO2017044766A1 (en) 2015-09-10 2017-03-16 Nivalis Therapeutics, Inc. Solid forms of an s-nitrosoglutathione reductase inhibitor
CN106008374B (zh) * 2016-06-07 2018-07-27 四川大学 吡嗪类化合物及其在医药上的用途
EP3351271A1 (en) * 2017-01-23 2018-07-25 TheraPharm GmbH Radioimmunoconjugate for use in treating bone marrow associated diseases
JP6831802B2 (ja) * 2018-01-12 2021-02-17 上海富吉医療器械有限公司Ｓｈａｎｇｈａｉ Ｃｈａｒｔｗｅｌｌ Ｍｅｄｉｃａｌ Ｉｎｓｔｒｕｍｅｎｔ Ｃｏ．， Ｌｔｄ． 放射性核種標識化合物及びこれを含有するイメージング剤
CN109776583A (zh) * 2019-01-25 2019-05-21 郑州大学 一种吡啶类链状共轭体系分子衍生物及其制备方法和应用
TWI759962B (zh) 2019-11-13 2022-04-01 香港商新旭生技股份有限公司 用於降解tau蛋白聚集體的化合物及其用途
CN113444036B (zh) * 2021-06-08 2022-10-04 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 一种二芳香基乙烯衍生物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790588A (en) * 1969-10-24 1974-02-05 Gulf Research Development Co Method of manufacturing dialkylamino-1,3,4-oxadiazoles and 1,3,4-thiadiazoles
US3743650A (en) * 1969-10-24 1973-07-03 Gulf Research Development Co 2-(2',5'-dimethylpyrrolidinyl)-5-aryl-1,3,4-thiadiazoles
DE2132937A1 (de) * 1971-07-02 1973-01-18 Agfa Gevaert Ag Spektral sensibilisierte direkt-positiv-emulsionsschichten
US3947337A (en) * 1973-05-10 1976-03-30 The Upjohn Company α,ω-Diarylpolyene photosensitizers for sulfonylazide polymers
NL174770C (nl) * 1978-09-04 1984-08-01 Hitachi Ltd Elektrofotografische plaat van het complexe type.
JPS58182640A (ja) * 1982-04-20 1983-10-25 Hitachi Ltd 複合型の電子写真用感光体
US4515883A (en) * 1983-04-14 1985-05-07 Ricoh Company, Ltd. Stilbene derivatives, distyryl derivatives and electrophotographic photoconductor comprising at least one of the derivatives
JPS59195658A (ja) * 1983-04-21 1984-11-06 Ricoh Co Ltd 電子写真用感光体
DE3418376A1 (de) * 1984-05-17 1985-11-21 Bayer Ag, 5090 Leverkusen Zwischenprodukte sowie verfahren zur herstellung von zwischenprodukten fuer die synthese von cephalosporinen
JPS61129650A (ja) * 1984-11-29 1986-06-17 Canon Inc 積層型電子写真感光体
JPS6210652A (ja) * 1985-07-08 1987-01-19 Minolta Camera Co Ltd 感光体
DE3706880A1 (de) * 1987-03-04 1988-09-15 Hoechst Ag 4-chloroxazol-derivate, verfahren zu ihrer herstellung und ihre verwendung
JPH01152461A (ja) * 1987-12-09 1989-06-14 Fuji Electric Co Ltd 電子写真用感光体
EP0321115B1 (en) * 1987-12-14 1991-08-14 Sawai Pharmaceutical Co., Ltd. Carboxamide derivatives having tetrazole and thiazole rings and their use
JPH0334967A (ja) * 1989-06-29 1991-02-14 Yoshitomi Pharmaceut Ind Ltd ブタン化合物またはその塩およびその医薬用途
JPH0383051A (ja) * 1989-08-28 1991-04-09 Konica Corp 高鮮鋭性を有するハロゲン化銀写真感光材料
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
JPH07128780A (ja) * 1993-11-05 1995-05-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
WO1997026919A2 (en) * 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
JP2001131151A (ja) * 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
ES2536449T3 (es) * 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Derivados de tioflavina para uso en diagnosis de la enfermedad de Alzheimer
GB0201179D0 (en) * 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents

Also Published As

Publication number Publication date
CR8230A (es) 2006-07-14
JPWO2005016888A1 (ja) 2006-10-12
KR20060037441A (ko) 2006-05-03
US20060018825A1 (en) 2006-01-26
RU2006107563A (ru) 2006-07-27
CN1867552A (zh) 2006-11-22
ECSP066363A (es) 2006-08-30
WO2005016384A1 (ja) 2005-02-24
BRPI0413556A (pt) 2006-10-17
IL173549A0 (en) 2006-07-05
AU2003304416A1 (en) 2005-03-07

Similar Documents

Publication Publication Date Title
NO20061169L (no) Prober for sykdommer hvor amyloid akkumulerer midler for a farge amyloidlegemidler for behandling og profylakse av sykdommer med akkumulert innhold og prober for diagnoser av nevrofibrilaere knuter og legemidler for a farge nevrofibrilaere knuter
Burkhardt et al. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients
EP1547996A4 (en) DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES HAVING PRION PROTEIN ACCUMULATION AND METHOD OF MARKING
MY146476A (en) Method of diagnosing lawsonia intracellularis
MA30250B1 (fr) Vaccins destines a lutter contre une infection a chlamydia
ATE533061T1 (de) Verfahren zur diagnose bakterieller infektionen
NO20051985L (no) Indazoler, benzotiazoler og benzoisotiazoler, samt fremstilling og anvendelser derav.
DE60136272D1 (de) Diagnostika und therapeutika für makula degeneration erkrankungen
DK1836312T3 (da) Fremgangsmåder og sammensætninger til diagnosticeringer af aldersrelateret makulær degeneration
CY1112737T1 (el) Ισοτοπικα σεσημασμενες ενωσεις βενζοfuran σαν παραγοντες απεικονισης για πρωτεϊνες δημιουργιας αμυλοειδους (αμυloid)
NO20045281L (no) Tiazolidinoner og anvendelse derav som polo-lignende kinaseinhibitorer
ATE464090T1 (de) Absperrhahn für medizinischen behandlung
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
DK1673475T3 (da) Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt
NO20072120L (no) Enzyme Inhibitor Imaging Agents
BR0208870A (pt) Proteìna associada à doença
BR0108802A (pt) Métodos de diagnóstico e terapêuticos para glaucoma
DE69628336D1 (de) Behandlung und diagnose helicobacter pylori infektionen
BR0014150A (pt) Diagnósticos e terapêuticos para osteoporose
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
NO20044550L (no) Heterotrisyklyl 6-alkaliden-penemer som beta-laktamaseinhibitorer
ATE400273T1 (de) 1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)- ethylcyclohexanol-derivate als monoamin- wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen
ATE419902T1 (de) Verwendung von epothilonen bei der behandlung von neuronalen verbindungsdefekten wie schizophrenie und autismus
UA88307C2 (en) Method for diagnostics of lawsonia intracellularis
FR2870241A1 (fr) Facteur de viabilite des cones derive des batonnets ou rdcvf et applications

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application